A new therapy to prevent the 
progression of COVID-19

Biomarker and AI-supported FX06 therapy to prevent the progression from mild and moderate to severe stages of COVID-19
10 M €
ALLOCATED BUDGET
17
PARTNERS
13
EUROPEAN COUNTRIES
9
HOSPITALS
3
SMEs

The aim of the COVend Consortium is to deliver a new effective therapy against SARS-CoV-2 for the clinical management of the COVID-19 disease.

The COVend Consortium sets up to prevent COVID-19 progression to severe disease status by targeting endothelial dysfunction.

Some of the technologies involved in the process will be OMICs technologies for biomarker profiling, research on endothelial cell damage and AI for Data Analytics and modelling. 

From Ebola to COVID-19

Having cured a patient with Ebola, it was clear to Prof. Zacharowski that FX06 could also be beneficial against COVID-19.

Meet COVend partners

COVend involves partners from all over Europe, with a variety of clinical sites based in different European countries, enabling the delivery of FX06 as a promising candidate to prevent progression from mild & moderate to severe stages of COVID-19. Hear from some COVend partners and discover how COVend is making a difference today!

News

image depicting two SDG icons

COVend and UN SDGs: Contributing to Shaping a Healthier World

In 2015, the United Nations adopted the 17 Sustainable Development Goals (SDGs) as a global blueprint for addressing pressing challenges. These goals guide our efforts to combat poverty, inequality, climate change, and environmental concerns. Among them, two pivotal goals stand out – SDG 3: Good Health and Well-being, and SDG 9: Industry, Innovation and Infrastructure.

Read More »